Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=55d60262-6207-449f-a491-0b695c16613b
Date 3/27/2014
Company Name RuiYi
Mailing Address 505 Coast Blvd S. La Jolla, CA 92037 USA
Company Description RuiYi is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer.
Proceeds Purposes The financing will support the continued development of RuiYi’s lead asset, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb), and the discovery and development of new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target.